Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 44, Issue 11, 2010, Pages 1777-1785

  Kerr, Jessica L ^a   Timpe, Erin M ^a   Petkewicz, Katherine A ^a  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

Bromocriptine; Circadian rhythm; Diabetes

Indexed keywords

BROMOCRIPTINE MESILATE; CARBAMAZEPINE; CHLORAMPHENICOL; CLOZAPINE; CYCLOSET; GLUCOSE; HEMOGLOBIN A1C; MACROLIDE; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROBENECID; PYRROLE DERIVATIVE; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

CIRCADIAN RHYTHM; CLINICAL TRIAL; DIABETIC PATIENT; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FIBROSIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HALLUCINATION; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INCIDENCE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSYCHOSIS; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; SOMNOLENCE; SYNCOPE; VOMITING;

AGED; ANIMALS; BLOOD GLUCOSE; BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; DOPAMINE AGONISTS; DRUG INTERACTIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RECEPTORS, DOPAMINE D2;

EID: 78049465403     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P271     Document Type: Review

References (18)

1. Drugs@FDA. US Food and Drug Administration. www.accessdata.fda. gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.DrugDetails (accessed 2010 Jun 28).
2. Meier AH, Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1996;4:464-87.
3. Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999;8:1683-707.
4. Barnard ND, Noble EP, Ritchie T, et al. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition 2009;25:58-65.
5. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet 2001;357:354-7.
6. Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type 2 diabetes. Indian J Pharmacol 2009;41:197-8.
7. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23:1154-61.
8. Dowse G, Zimmet P. The thrifty genotype in non-insulin dependent diabetes mellitus. BMJ 1993;306:532-3.
9. Luo S, Luo J, Cincotta AH. Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism with the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int 2000;17:155-72.
10. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord 2007;7:3.
11. Prescribing information. Cycloset (bromocriptine mesylate). Research Triangle Park, NC: VeroScience LLC, April 2009.
12. Barnett AH, Chapman C, Gailer K, Hayter CJ. Effect of bromocriptine on maturity onset diabetes. Postgrad Med J 1980;56:11-4.
13. Scranton R, Cincotta A. Bromocriptine - unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010;11:269-79.
14. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick release-bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33: 1503-8.
15. Gaziano JM, Ezrokhi M, Cincotta AH, Scranton RE. Effects of timed Cycloset (a quick release formulation of bromocriptine mesylate) administration on safety, cardiovascular event rate and glycemic control in subjects with type 2 diabetes receiving diet, oral hypoglycemic and/or insulin treatment regimens (abstract). Diabetes 2007;56(suppl 1A):50-LB.
16. Cincotta AH, Gaziano JM, Ezrohi M, Scranton R. Cycloset (quick-release bromocriptine mesylate), a novel centrally acting treatment for type 2 diabetes (abstract). Diabetologia 2008;51(suppl 1):S22.
17. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type 2 diabetes? Horm Res 2004;62:55-69.
18. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 1992;48:248-53.